60 related articles for article (PubMed ID: 18476769)
1. Effective induction of type 1 helper IgG2a and cytotoxic T-cell responses in mice following immunization with human papillomavirus type 16 E2 in MF59.
Heinemann L; Woodfield L; Amer M; Hibma M
Viral Immunol; 2008 Jun; 21(2):225-33. PubMed ID: 18476769
[TBL] [Abstract][Full Text] [Related]
2. A vaccine conjugate of 'ISCAR' immunocarrier and peptide epitopes of the E7 cervical cancer-associated protein of human papillomavirus type 16 elicits specific Th1- and Th2-type responses in immunized mice in the absence of oil-based adjuvants.
Tindle RW; Croft S; Herd K; Malcolm K; Geczy AF; Stewart T; Fernando GJ
Clin Exp Immunol; 1995 Aug; 101(2):265-71. PubMed ID: 7544248
[TBL] [Abstract][Full Text] [Related]
3. [Heat-shock protein enhances immunogenicity of E7 oncoprotein of human papillomavirus included in chimeric construction (E7 HPV-HSP70)].
Sveshnikov PG; Solopova ON; Kurbatova EA; Shevchik IuS; Baranovskiĭ PM; Ul'ianov AM; Bokov MN; Kiselev VI
Zh Mikrobiol Epidemiol Immunobiol; 2010; (3):36-9. PubMed ID: 20734716
[TBL] [Abstract][Full Text] [Related]
4. Enhanced immunogenicity of HPV16E7 accompanied by Gp96 as an adjuvant in two vaccination strategies.
Bolhassani A; Zahedifard F; Taghikhani M; Rafati S
Vaccine; 2008 Jun; 26(26):3362-70. PubMed ID: 18471945
[TBL] [Abstract][Full Text] [Related]
5. Resolution of cervical dysplasia is associated with T-cell proliferative responses to human papillomavirus type 16 E2.
Dillon S; Sasagawa T; Crawford A; Prestidge J; Inder MK; Jerram J; Mercer AA; Hibma M
J Gen Virol; 2007 Mar; 88(Pt 3):803-813. PubMed ID: 17325352
[TBL] [Abstract][Full Text] [Related]
6. A novel "priming-boosting" strategy for immune interventions in cervical cancer.
Liao S; Zhang W; Hu X; Wang W; Deng D; Wang H; Wang C; Zhou J; Wang S; Zhang H; Ma D
Mol Immunol; 2015 Apr; 64(2):295-305. PubMed ID: 25575128
[TBL] [Abstract][Full Text] [Related]
7. The adjuvant effect of MF59 is due to the oil-in-water emulsion formulation, none of the individual components induce a comparable adjuvant effect.
Calabro S; Tritto E; Pezzotti A; Taccone M; Muzzi A; Bertholet S; De Gregorio E; O'Hagan DT; Baudner B; Seubert A
Vaccine; 2013 Jul; 31(33):3363-9. PubMed ID: 23684834
[TBL] [Abstract][Full Text] [Related]
8. Antibody and T-cell responses to a virosomal adjuvanted H9N2 avian influenza vaccine: impact of distinct additional adjuvants.
Radosević K; Rodriguez A; Mintardjo R; Tax D; Bengtsson KL; Thompson C; Zambon M; Weverling GJ; Uytdehaag F; Goudsmit J
Vaccine; 2008 Jul; 26(29-30):3640-6. PubMed ID: 18514980
[TBL] [Abstract][Full Text] [Related]
9. MF59 Mediates Its B Cell Adjuvanticity by Promoting T Follicular Helper Cells and Thus Germinal Center Responses in Adult and Early Life.
Mastelic Gavillet B; Eberhardt CS; Auderset F; Castellino F; Seubert A; Tregoning JS; Lambert PH; de Gregorio E; Del Giudice G; Siegrist CA
J Immunol; 2015 May; 194(10):4836-45. PubMed ID: 25870238
[TBL] [Abstract][Full Text] [Related]
10. Plasmid DNA vaccines are effective in the absence of IFNgamma.
Hassett DE; Zhang J; Whitton JL
Virology; 1999 Oct; 263(1):175-83. PubMed ID: 10544092
[TBL] [Abstract][Full Text] [Related]
11. Both E7 and CpG-oligodeoxynucleotide are required for protective immunity against challenge with human papillomavirus 16 (E6/E7) immortalized tumor cells: involvement of CD4+ and CD8+ T cells in protection.
Kim TY; Myoung HJ; Kim JH; Moon IS; Kim TG; Ahn WS; Sin JI
Cancer Res; 2002 Dec; 62(24):7234-40. PubMed ID: 12499264
[TBL] [Abstract][Full Text] [Related]
12. An improved rearranged Human Papillomavirus Type 16 E7 DNA vaccine candidate (HPV-16 E7SH) induces an E7 wildtype-specific T cell response.
Ohlschläger P; Pes M; Osen W; Dürst M; Schneider A; Gissmann L; Kaufmann AM
Vaccine; 2006 Apr; 24(15):2880-93. PubMed ID: 16472545
[TBL] [Abstract][Full Text] [Related]
13. A novel adjuvant, the general opioid antagonist naloxone, elicits a robust cellular immune response for a DNA vaccine.
Jamali A; Mahdavi M; Hassan ZM; Sabahi F; Farsani MJ; Bamdad T; Soleimanjahi H; Motazakker M; Shahabi S
Int Immunol; 2009 Mar; 21(3):217-25. PubMed ID: 19174474
[TBL] [Abstract][Full Text] [Related]
14. Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice.
Wack A; Baudner BC; Hilbert AK; Manini I; Nuti S; Tavarini S; Scheffczik H; Ugozzoli M; Singh M; Kazzaz J; Montomoli E; Del Giudice G; Rappuoli R; O'Hagan DT
Vaccine; 2008 Jan; 26(4):552-61. PubMed ID: 18162266
[TBL] [Abstract][Full Text] [Related]
15. Th2-type CD4+ cells neither enhance nor suppress antitumor CTL activity in a mouse tumor model.
Fernando GJ; Stewart TJ; Tindle RW; Frazer IH
J Immunol; 1998 Sep; 161(5):2421-7. PubMed ID: 9725239
[TBL] [Abstract][Full Text] [Related]
16. Cationic microparticles are a potent delivery system for a HCV DNA vaccine.
O'Hagan DT; Singh M; Dong C; Ugozzoli M; Berger K; Glazer E; Selby M; Wininger M; Ng P; Crawford K; Paliard X; Coates S; Houghton M
Vaccine; 2004 Dec; 23(5):672-80. PubMed ID: 15542189
[TBL] [Abstract][Full Text] [Related]
17. Systemic cytokine profiles in BALB/c mice immunized with trivalent influenza vaccine containing MF59 oil emulsion and other advanced adjuvants.
Valensi JP; Carlson JR; Van Nest GA
J Immunol; 1994 Nov; 153(9):4029-39. PubMed ID: 7930610
[TBL] [Abstract][Full Text] [Related]
18. Frequent detection of human papillomavirus 16 E2-specific T-helper immunity in healthy subjects.
de Jong A; van der Burg SH; Kwappenberg KM; van der Hulst JM; Franken KL; Geluk A; van Meijgaarden KE; Drijfhout JW; Kenter G; Vermeij P; Melief CJ; Offringa R
Cancer Res; 2002 Jan; 62(2):472-9. PubMed ID: 11809698
[TBL] [Abstract][Full Text] [Related]
19. Influenza vaccine: development of a novel intranasal and subcutaneous recombinant adjuvant.
Segura-Velázquez R; Cervantes J; Acosta E; Sánchez-Betancourt I; Villalobos N; Rodarte LF; Restelli M; Fragoso G; Sciutto E
Vaccine; 2013 Aug; 31(37):4009-16. PubMed ID: 23746458
[TBL] [Abstract][Full Text] [Related]
20. Enhancement of T cell-mediated and humoral immunity of beta-glucuronidase-based DNA vaccines against HPV16 E7 oncoprotein.
Smahel M; Poláková I; Pokorná D; Ludvíková V; Dusková M; Vlasák J
Int J Oncol; 2008 Jul; 33(1):93-101. PubMed ID: 18575754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
